Engineering bone regeneration: Strontium fluorophosphate, incorporation into collagen and gelatin-based hydrogels promotes osteogenesis in human adipose-derived mesenchymal stem cells.
Noori S., Norouz F., Halabian R., Aghamollaei H., Eftekhari E., Salimi A.
Laboratory Study, published in Tissue Cell (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Tissue Cell (2025)
- Country
- Scotland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 41478022
- DOI
- 10.1016/j.tice.2025.103292
Abstract (original English)
Background The incorporation of nanoparticles into hydrogels enhances their properties for biomedical applications. Strontium can enhance osteogenesis through osteoblast formation by substituting calcium in osteoblast-mediated processes. Materials and methods Collagen-gelatin hydrogels (COL-GEL) were synthesized with and without strontium fluorophosphate (SrFP) to study their effect on osteogenic differentiation of adipose-derived mesenchymal stem cells (AD-MSCs). Scaffolds were characterized using XRD and FTIR. Biocompatibility of SrFP and scaffolds was assessed using the MTT assay and acridine orange. Their osteogenic differentiation potential was evaluated by ALP activity, calcium content, alizarin red, von Kossa staining, real-time RT-PCR and immunocytochemistry. Results SrFP at 50 μg/ml significantly promoted proliferation by 1.5-fold over 3 days. The COL-GEL-0.1 %SrFP scaffold showed higher cell proliferation compared to COL-GEL-0.5 %SrFP. The COL-GEL-SrFP exhibited high ALP activity (1.5-fold enhancement) and calcium content (2.1-fold enhancement), consistent with the results of alizarin red (p ≤ 0.05) and von Kossa (p ≤ 0.01). Gene and protein analyses revealed the elevated levels of ALP, Col-I (1.6-fold), osteocalcin (1.7-fold) and RUNX2 (2.3-fold) gene expression, as well as a significant upregulation of osteocalcin and osteopontin protein levels (more than 3-fold) in
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.